Literature DB >> 27476474

Management of glioblastoma after recurrence: A changing paradigm.

Supriya Mallick1, Rony Benson2, Abdul Hakim2, Goura K Rath2.   

Abstract

Glioblastoma remains the most common primary brain tumor after the age of 40years. Maximal safe surgery followed by adjuvant chemoradiotherapy has remained the standard treatment for glioblastoma (GBM). But recurrence is an inevitable event in the natural history of GBM with most patients experiencing it after 6-9months of primary treatment. Recurrent GBM poses great challenge to manage with no well-defined management protocols. The challenge starts from differentiating radiation necrosis from true local progression. A fine balance needs to be maintained on improving survival and assuring a better quality of life. Treatment options are limited and ranges from re-excision, re-irradiation, systemic chemotherapy or a combination of these. Re-excision and re-irradiation must be attempted in selected patients and has been shown to improve survival outcomes. To facilitate the management of GBM recurrences, a treatment algorithm is proposed.
Copyright © 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bevacizumab; Chemotherapy; Glioblastoma; NovoTTF; Re-irradiation; Recurrent

Mesh:

Year:  2016        PMID: 27476474     DOI: 10.1016/j.jnci.2016.07.001

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  22 in total

Review 1.  Paediatric gliomas: diagnosis, molecular biology and management.

Authors:  Alexandros Blionas; Dimitrios Giakoumettis; Alexia Klonou; Eleftherios Neromyliotis; Ploutarchos Karydakis; Marios S Themistocleous
Journal:  Ann Transl Med       Date:  2018-06

2.  High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.

Authors:  Padma Kadiyala; Dan Li; Fernando M Nuñez; David Altshuler; Robert Doherty; Rui Kuai; Minzhi Yu; Neha Kamran; Marta Edwards; James J Moon; Pedro R Lowenstein; Maria G Castro; Anna Schwendeman
Journal:  ACS Nano       Date:  2019-02-11       Impact factor: 15.881

Review 3.  Glycomaterials to Investigate the Functional Role of Aberrant Glycosylation in Glioblastoma.

Authors:  Chaitanya Tondepu; Lohitash Karumbaiah
Journal:  Adv Healthc Mater       Date:  2021-12-29       Impact factor: 11.092

Review 4.  The impact of mitochondria on cancer treatment resistance.

Authors:  Michelle van der Merwe; Gustav van Niekerk; Carla Fourie; Manisha du Plessis; Anna-Mart Engelbrecht
Journal:  Cell Oncol (Dordr)       Date:  2021-07-09       Impact factor: 6.730

Review 5.  Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma.

Authors:  Anna Schritz; Nassera Aouali; Aurélie Fischer; Coralie Dessenne; Roisin Adams; Guy Berchem; Laetitia Huiart; Susanne Schmitz
Journal:  Neurooncol Adv       Date:  2021-04-09

Review 6.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

7.  Modification and optimization of an established prognostic score after re-irradiation of recurrent glioma.

Authors:  Kerstin A Kessel; Josefine Hesse; Christoph Straube; Claus Zimmer; Friederike Schmidt-Graf; Jürgen Schlegel; Bernhard Meyer; Stephanie E Combs
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

8.  Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion.

Authors:  Noemi García-Romero; Irina Palacín-Aliana; Susana Esteban-Rubio; Rodrigo Madurga; Sergio Rius-Rocabert; Josefa Carrión-Navarro; Jesús Presa; Sara Cuadrado-Castano; Pilar Sánchez-Gómez; Adolfo García-Sastre; Estanislao Nistal-Villan; Angel Ayuso-Sacido
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

9.  Cell Cycle Changes after Glioblastoma Stem Cell Irradiation: The Major Role of RAD51.

Authors:  Gaelle Tachon; Ulrich Cortes; Pierre-Olivier Guichet; Pierre Rivet; Anais Balbous; Konstantin Masliantsev; Antoine Berger; Odile Boissonnade; Michel Wager; Lucie Karayan-Tapon
Journal:  Int J Mol Sci       Date:  2018-10-03       Impact factor: 5.923

10.  A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis.

Authors:  Montserrat Lara-Velazquez; Jack M Shireman; Eric J Lehrer; Kelsey M Bowman; Henry Ruiz-Garcia; Mitchell J Paukner; Richard J Chappell; Mahua Dey
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.